Corteva, Inc. (CTVA) Stock Price & How to Invest

Corteva was formed in 2019 when DowDuPont spun off its agriculture business, and for most of its life it ran two segments: Seed (genetically improved corn, soybean, canola, and other crop seeds) and Crop Protection (herbicides, insecticides, fungicides, and biological products). That structure ended in October 2026, when Corteva completed the separation of its seed operations into a new independent company, Vylor Inc., which trades under the ticker VYLR. Corteva keeps the NYSE listing and the CTVA ticker as a crop protection and digital agriculture business, with a standalone revenue base reported at about $7.5 billion and projected 2025 EBITDA of about $1.4 billion. Headquartered in Indianapolis, Indiana. Chuck Magro has been CEO since 2021.

The separation changes what the stock is. Before the spin, the higher-margin seed franchise cushioned swings in chemistry; now CTVA's revenue and earnings move with crop protection volumes and pricing, which have been pressured over the past three years by generic products from China and India. That pressure is easing and industry volumes have returned to growth, according to an October 2026 UBS note, but UBS also expects rising raw material costs into 2027 and modeled only about 3% organic growth through 2029. The smaller company has moved down the index ladder, with October 2026 reports noting its addition to the S&P MidCap 400 and S&P 1000. On the October 16, 2026 close of $12.94, CTVA had a market cap near $8.6 billion and traded around 11 times consensus 2026 EPS of about $1.11. Lawsuits have also questioned whether PFAS-related legacy liabilities were allocated fairly between Corteva and Vylor in the split, a risk that stays with the CTVA shareholder.

Commodity crop price cycles affect farmer purchasing power and Corteva revenue, and the company no longer has the seed business to cushion a weak chemistry year. Generic competition from China and India has pressured crop protection prices for three years, and rising raw material costs into 2027 could squeeze margins before new products contribute. Weather conditions affect crop years and product demand. Regulatory pressure on certain herbicides (atrazine, paraquat) creates product-level risks. Legacy PFAS liabilities, and litigation over how they were allocated between Corteva and Vylor in the separation, are an open exposure. Peer turmoil is a live signal: FMC's October 2026 guidance cut prompted at least one analyst (Citi) to expect a modest negative read-across to Corteva. Post-spin, many trailing figures on data sites mix pre- and post-separation periods, so headline P/E, yield and growth numbers should be read with care.

12 analysts publish price targets on CTVA, averaging $22.05 against a $12.88 price as of October 2026, or +71.2%. The published targets run from $13.65 to $75.00, a wide spread, and the ratings split 9 buy, 3 hold, 0 sell. Over the last six months there have been 4 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CTVA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Corteva, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. A pure crop protection company after the Vylor spin-off. With the seed business now at Vylor, CTVA's results depend on crop chemistry and biologicals alone. The most optimistic published target, $75.00, assumes this works close to its best case.

The case against. Commodity crop price cycles affect farmer purchasing power and Corteva revenue, and the company no longer has the seed business to cushion a weak chemistry year. The most pessimistic target, $13.65, is roughly what CTVA is worth if this bites instead.

Read the full bull and bear case on CTVA, including what would have to change to break either one. Walnut is not an investment adviser.

No. Corteva, Inc. (CTVA) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Corteva, Inc.'s investor relations page or your broker.

• Standalone revenue base (crop protection and digital): ~$7.5 billion, per post-spin reports
• Standalone EBITDA (2025, projected): ~$1.4 billion
• Operating margin (TTM, Yahoo basis): ~13%
• Market cap: ~$8.6 billion at $12.94 (Oct 16, 2026)
• Forward P/E: ~11x consensus 2026 EPS of ~$1.11
• 2027 EPS consensus: ~$1.13, revenue ~$8.1 billion
• Cash / debt: ~$1.9 billion / ~$4.8 billion

Post-spin Corteva is valued as a mid-cap crop chemicals company: about 11 times forward earnings and roughly $8.6 billion of market value, a long way from the premium the combined seed-and-chemistry company carried. Trailing figures on data sites (a P/E near 8, a dividend yield above 5%, TTM net income of ~$126 million) mix pre- and post-separation periods and per-share bases, so they are not a clean guide yet. UBS cut its price target to $15 from $90 with a Neutral rating; the cut tracks the smaller standalone company rather than a change in view, and the November 11, 2026 report will give the first clean standalone baseline.

If you want CTVA exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses CTVA naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to CTVA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CTVA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (MOO, GNR, GUNR), which spreads the position across many companies. Or build it into a focused thematic portfolio, so CTVA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CTVA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Corteva (CTVA) now gives exposure to the crop protection side of agriculture only, after the October 2026 spin-off of its seed business as Vylor. In a portfolio it sits as a cyclical materials and agriculture holding, often paired with Deere (DE) as the input layer to Deere's equipment layer, competing with Bayer, BASF, Syngenta, and FMC, and sensitive to crop prices, generic pricing pressure from China and India, weather, and herbicide regulation.

Whether CTVA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CTVA a buy or a sell?, and where the stock could go from here in the CTVA stock forecast.

For income investors, whether CTVA pays a dividend and how the payout looks is covered in does CTVA pay a dividend? And to weigh CTVA against a peer, read the full side-by-side comparisons: CTVA vs DE and CTVA vs CALM.